|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-2.75/-64.98
|
Enterprise Value
33.85M
|
Balance Sheet |
Book Value Per Share
-0.59
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
12.00M
|
Operating Revenue Per Share
0.53
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 08:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment. |